Absci Corporation

Absci Corporation (ABSI) Market Cap

Absci Corporation has a market capitalization of $563.1M.

Financials based on reported quarter end 2025-12-31

Price: $3.68

โ–ผ -0.22 (-5.64%)

Market Cap: 563.12M

NASDAQ ยท time unavailable

CEO: Sean McClain

Sector: Healthcare

Industry: Biotechnology

IPO Date: 2021-07-22

Website: https://www.absci.com

Absci Corporation (ABSI) - Company Information

Market Cap: 563.12M ยท Sector: Healthcare

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Analyst Sentiment

69%
Buy

Based on 12 ratings

Analyst 1Y Forecast: $6.16

Average target (based on 2 sources)

Consensus Price Target

Low

$4

Median

$6

High

$8

Average

$6

Potential Upside: 67.4%

Price & Moving Averages

Loading chart...

๐Ÿ“˜ Full Research Report

โ„น๏ธ

AI-Generated Research: This report is for informational purposes only.

๐Ÿ“˜ ABSCI CORP (ABSI) โ€” Investment Overview

๐Ÿงฉ Business Model Overview

ABSCI CORP operates as a specialty provider serving customers that require mission-critical services in regulated or compliance-heavy environments. The value chain typically starts with customer needs (performance, reliability, traceability, and adherence to standards), followed by qualification and onboarding processes, then delivery through ongoing service execution and documentation. Revenue is earned by moving customers from an initial evaluation or project stage into repeatable consumption patternsโ€”supported by compliance documentation, process know-how, and established operational workflows.

Customer stickiness tends to come less from โ€œbrandโ€ and more from execution credibility: once an organization integrates a vendor into its internal operating procedures (procurement, compliance workflows, audits, and supplier approvals), switching can introduce operational downtime, validation burden, and perceived risk.

๐Ÿ’ฐ Revenue Streams & Monetisation Model

Monetisation is driven by a blend of transactional work and longer-duration engagements. For ABSI, the economic model generally reflects:

  • Service/solution delivery revenue tied to project execution, customer-specific requirements, and measurable outputs.
  • Recurring revenue components that arise from repeat orders, renewals, and expanded scopes after successful initial deployments.
  • Margin drivers including utilization of specialist resources, economies from standardized processes, and pricing power once customers have completed qualification and internal validation.

Operating leverage is most likely to emerge when delivery processes can be standardized while maintaining compliance. Conversely, margins can compress when project mix requires disproportionate engineering or when contractual pricing lags input-cost inflation.

๐Ÿง  Competitive Advantages & Market Positioning

The primary moat is switching costs and process/intangible-based differentiation, supported by compliance and qualification dynamics.

  • Switching costs (hard to replicate): customers often incur re-qualification costs, audit rework, and operational risk when changing suppliers. Supplier approval cycles and internal validation can be lengthy.
  • Intangible assets (know-how and documentation): expertise in regulatory/compliance execution, customer-specific protocols, and repeatable operational playbooks tends to compound over time.
  • Operational credibility: outcomes tied to reliability and auditability create an advantage that is difficult to win quickly through marketing or price cuts.

A competitor can enter the market, but taking share usually requires overcoming qualification hurdles and proving performance consistentlyโ€”an investment that can delay payback. This structure favors incumbents that have already embedded themselves into customersโ€™ supplier ecosystems.

๐Ÿš€ Multi-Year Growth Drivers

Over a 5โ€“10 year horizon, growth is likely to be supported by secular demand for reliable, compliant, and auditable solutions. Key drivers include:

  • Regulatory and compliance intensity: compliance requirements typically increase total spend on qualified providers and documentation-heavy execution.
  • Industrial and institutional modernization: enterprises upgrade systems and processes, expanding the addressable population of organizations that require specialized service partners.
  • Expansion of customer scope: after successful delivery, customers often extend usage into adjacent workflows, creating a pathway from early engagements to broader programs.
  • Institutional procurement cycles: once a vendor is approved, spend can become more predictable due to formal procurement cadence.

The TAM conceptually expands as more organizations adopt standardized processes that require qualified execution, while ABSIโ€™s share potential depends on its ability to scale delivery capacity without eroding compliance quality.

โš  Risk Factors to Monitor

  • Execution and quality risk: in compliance-heavy environments, any service quality lapse can trigger remediation, contractual disputes, or loss of approvals.
  • Customer concentration: reliance on a limited set of customers can amplify revenue volatility and negotiating leverage against ABSI.
  • Contract and pricing pressure: competitive bids can compress margins, especially when customers use cost benchmarking across suppliers.
  • Capital intensity and capacity planning: scaling specialized delivery may require upfront investment in people, systems, and compliance infrastructure.
  • Technological displacement: automation or alternative platforms could reduce the need for certain service components, shifting revenue mix toward fewer high-margin tasks or requiring productization.

These risks are structural in nature: even with strong demand, resilience depends on maintaining delivery capacity, compliance standards, and customer relationships through cycles.

๐Ÿ“Š Valuation & Market View

Equity markets commonly value specialty service and solution providers using EV/EBITDA or EV/Revenue frameworks, particularly when operating history is still building or cash flows are influenced by project timing. Key valuation sensitivities typically include:

  • Visibility of recurring revenue (renewals, repeat orders, multi-scope expansions).
  • Sustainable margins driven by utilization, process standardization, and pricing discipline.
  • Working capital dynamics tied to project billing cycles and collections.
  • Customer retention and order conversion from qualification-stage to repeat delivery.

A credible path to higher valuation usually reflects improvement in revenue predictability and durable unit economics rather than growth alone.

๐Ÿ” Investment Takeaway

ABSCI CORPโ€™s long-term investment case centers on durable switching costs and earned intangible assetsโ€”compliance execution, documented operational know-how, and embedded customer qualification. Multi-year growth potential depends on the expansion of compliance-driven demand and the ability to convert early engagements into repeatable, higher-margin scopes while scaling capacity without compromising quality. The core question for investors is whether ABSI can maintain delivery credibility and margin structure as it expands its customer base.


โš  AI-generated โ€” informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

๐Ÿ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"Headline (most recent quarter, 2025-12-31): Revenue $0.65M; Net Income -$29.56M (EPS -0.20). Revenue rose QoQ to $650K from $378K (+72% QoQ), but losses remained heavy and slightly worsened: net loss deepened modestly from -$28.71M to -$29.56M (about -3% QoQ in loss magnitude). Across the 4-quarter period, revenue was volatile (from $1.18M in 2025-03-31 down to $0.38M in 2025-09-30, then back to $0.65M), while profitability consistently deteriorated/failed to scale. Net margin remained deeply negative in every quarter (losses far exceed revenue), implying limited operating leverage so far. Cash flow quality is a key issue: operating cash flow and FCF were negative each quarter, with FCF worsening to -$29.08M in 2025-12-31 (from -$25.99M in 2025-09-30, -$17.10M in 2025-06-30, and -$21.86M in 2025-03-31). There are no dividends. Balance sheet resilience looks moderate: total assets are roughly stable (~$209Mโ€“$245M range) and equity remains positive ($189M latest), with net debt negative (net cash) improving flexibility. Total shareholder returns appear driven by price only: the stock is up +2.59% over 1Y, down -18.72% over 6M, and down -12.19% YTD; no yield/repurchase data is provided. Analyst target consensus (~$6.16) is above the current ~$3.17, but the valuation signal is not supported by improving cash generation."

Revenue Growth

Neutral

QoQ revenue improved in the latest quarter (+72% from $378K to $650K), but results were highly volatile across the 4-quarter window (peak $1.18M in 2025-03-31; trough $0.38M in 2025-09-30). YoY comparisons were not possible because prior-year quarters were not provided.

Profitability

Neutral

Net income remains deeply negative every quarter. Latest net loss was -$29.56M vs -$28.71M QoQ (loss slightly worse). EPS stayed around -0.20 to -0.24 with no evidence of margin expansion.

Cash Flow Quality

Neutral

FCF is consistently negative and worsening: -$29.08M in 2025-12-31 vs -$25.99M in 2025-09-30 and -$17.10M in 2025-06-30. No dividends; buybacks not indicated.

Leverage & Balance Sheet

Caution

Positive equity throughout and net debt is negative (net cash). Total assets and equity fluctuate but remain resilient (assets roughly $209Mโ€“$245M; equity ~$173Mโ€“$210M), suggesting less immediate leverage pressure.

Shareholder Returns

Neutral

1Y price change is modest (+2.59%) and below the >20% momentum threshold. 6M and YTD are negative (-18.72%, -12.19%). No dividend support is available and buyback data is not provided.

Analyst Sentiment & Valuation

Caution

Consensus target (~$6.16) and median ($6.16) are above the current ~$3.17, implying bullish analyst expectations; however, the lack of profitability/FCF improvement limits confidence in near-term fundamentals.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management sounded confident on clinical executionโ€”ABS-201 has dosed its first three SAD cohorts with โ€œfavorable emerging safety,โ€ and the team is already positioning Phase 3-ready development milestones (13-week interim POC in 2H26; 26-week in early 2027; endometriosis Phase 2 targeted for Q4 2026). However, the Q&A pressure points were efficacy thresholds and, more importantly, credibility of target engagement and safety interpretability. On efficacy, management defined a quantitative โ€œhome-runโ€ bar: terminal-area hair count growth consistent with high-dose oral minoxidil (35โ€“40 hairs/cmยฒ), but acknowledged the path still depends on early readouts. On safety, they reiterated no clear on-target/off-target TEAE mechanism signals yet, while caveating that exposure is still limitedโ€”an early-trial constraint. On the biggest technical skepticism (antibody delivery to hair follicles for PRLR inhibition), management defended the claim with animal biodistribution/occupancy modeling rather than human efficacy data. Overall tone: optimistic, but investors are still waiting for data to validate efficacy durability and mechanistic proof.

AI IconGrowth Catalysts

  • ABS-201 dosed first three SAD cohorts in Phase 1/2a with favorable emerging safety data
  • Expanded ABS-201 into endometriosis as a second indication
  • Published de novo, full-length antibody design to zero prior epitopes (OriginOne platform output)

Business Development

  • Ongoing (not yet disclosed) platform partnership discussions with large pharma (qualitative only); negotiating deal structures
  • Planned partnering for oncology programs ABS-301 and ABS-501; internal development deprioritized for oncology

AI IconFinancial Highlights

  • Q4 revenue: $0.7 million (partnered programs)
  • Q4 R&D expense: $25.3 million vs $18.4 million prior-year period (increase driven by ABS-101/ABS-201 external preclinical/clinical direct costs)
  • Q4 SG&A: $8.6 million vs $8.8 million prior-year period
  • 2025 contingent consideration: $5.1 million gain on settlement; generated net proceeds of $8.7 million of unrestricted cash
  • Cash, cash equivalents & marketable securities: $144.3 million (Dec 31, 2025) vs $152.5 million (Sep 30, 2025)
  • Cash runway: management expects existing cash to fund operations into 2028

AI IconCapital Funding

    AI IconStrategy & Ops

    • Clinical operations: on track to dose SAD cohort four and first MAD cohort
    • ABS-201 trial design: MAD portion powered to demonstrate proof of concept in AGA; 227 healthy volunteer enrollment (SAD: 4 IV dose groups; MAD: 3 SC MAD groups)
    • Clinical/BD strategy: focus resources on ABS-201; partner oncology (301/501); nominate de novo internal programs in I&I later this year

    AI IconMarket Outlook

    • ABS-201 expected milestones: preliminary safety/PK in first half 2026; interim 13-week POC hair regrowth data in second half 2026; full 26-week POC hair regrowth data in early 2027
    • Endometriosis: Phase 2 initiation targeted for Q4 2026 ("beginning in Q4" subject to data/regulatory review); interim POC readout from Phase 1/2a in 2027
    • Potential FDA development pathway: management engaged with FDA re: efficient strategy; potential advancement from Phase 1/2a directly into Phase 3 (not yet engaged on Phase 3 design)

    AI IconRisks & Headwinds

    • Safety/TEAE uncertainty: management stated no evidence of on-target/off-target safety signal so far, but emphasized it is early and exposure is limited ("onesie-twosie" events; labs monitored closely)
    • Efficacy hurdle framing: success threshold tied to achieving terminal-area hair count growth consistent with high-dose oral minoxidil (~35 to 40 hairs/cm^2); management says significant product even below that
    • Target engagement / tissue penetration skepticism addressed: investor concern about follicle penetration to inhibit PRLR; management relies on stump-tail macaque and mouse data plus receptor occupancy modeling using scalp/follicle biodistribution coefficient lower than other tissues (explicitly: does not expect whole-body biodistribution typical of other organs, but claims adequate blood flow into follicle)

    Sentiment: CAUTIOUS

    Note: This summary was synthesized by AI from the ABSI Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

    Loading financial data and tables...
    ๐Ÿ“

    SEC Filings (ABSI)

    ยฉ 2026 Stock Market Info โ€” Absci Corporation (ABSI) Financial Profile